Tilray Brands Announces Major Strategic Moves: Lyphe Acquisition, BrewDog Expansion, and U.S. Medical Cannabis Readiness

Key Highlights for Investors

• Acquisition of Lyphe Group: Tilray expands its UK healthcare footprint with the purchase of Lyphe Group, a leading medical cannabis clinic and digital pharmacy platform.
• BrewDog Growth Initiatives: Following its recent acquisition, Tilray is accelerating BrewDog’s global expansion and revitalizing its brewpub network.
• U.S. Medical Cannabis Positioning: The company is strategically prepared for potential U.S. cannabis rescheduling and entry into the regulated medical cannabis market.
• ATM Equity Program Filed: Tilray has filed a \$180 million at-the-market (ATM) equity program to support beverage platform growth and maintain financial flexibility.

Strategic Moves Detailed

Lyphe Group Acquisition: Expanding UK Medical Cannabis Ecosystem

Tilray Brands has acquired the Lyphe Group, a prominent UK-based medical cannabis clinic and digital pharmacy platform. Lyphe Dispensary has dispensed approximately 150,000 units, and Lyphe Clinic has treated over 16,000 patients. The acquisition positions Tilray Medical as a leading, fully vertically integrated, patient-centric platform in Europe’s dynamic healthcare market.

• Integration Benefits: Tilray will combine clinical services, patient access, and pharmaceutical distribution, creating a seamless, digitally enabled patient experience.
• CC Pharma Synergies: Leveraging CC Pharma’s scale, sourcing, and purchasing power will allow more efficient medication supply and further strengthen Tilray’s European pharmaceutical distribution network.
• Financial Impact: Tilray expects the Lyphe business to be accretive by 2027, offering enhanced profitability and growth potential.

BrewDog: Stabilizing, Scaling, and Innovating for Global Growth

Six weeks after acquiring BrewDog, Tilray has stabilized brewing volumes, maintained service levels, and begun onboarding new distribution and strategic partners. The company is reinvesting in BrewDog’s brand, innovation pipeline, and brewpub experience, with a clear path to rebuilding BrewDog toward its previous valuation of over \$1 billion.

• Expansion Targets: Plans to scale BrewDog across the UK, Australia, the U.S., and key markets like the Middle East and India.
• Operational Improvements: Investments in the revitalization and modernization of the brewpub estate, including a “brewpub of the future” concept, are underway.
• Cash Flow Positive by 2027: BrewDog is expected to deliver positive cash flow in 2027, providing a strong foundation for long-term growth.
• American Craft Brands: Strong demand in the UK presents near-term opportunities to expand Tilray’s American craft portfolio. Hi*Ball Energy will launch in the UK in May to capture demand in the fast-growing functional beverage category.

U.S. Medical Cannabis Opportunity: Strategic Readiness for Rescheduling

Tilray is actively engaging with U.S. legislators and regulators as the potential for medical cannabis rescheduling advances. The company is evaluating participation in the Center for Medicare and Medicaid Innovation pilot program, aiming to supply underserved patients with hemp-derived medical cannabis and gather outcome data.

• Global Expertise: Tilray Medical operates in over 20 markets, with a proven track record in pharmaceutical-grade cultivation, manufacturing, and distribution.
• Product Portfolio: The company provides a broad range of CBD and THC products (beverages, edibles, topicals) and has supported hundreds of thousands of patients worldwide.
• Potential Market Impact: Upon rescheduling, Tilray expects to be well-positioned to seize opportunities in a regulated U.S. medical cannabis market.

ATM Equity Program: Enhancing Financial Flexibility

Tilray has filed an at-the-market equity program of up to \$180 million to invest in its global beverage platform and maintain a strong balance sheet. The ATM will be managed by Jefferies LLC, TD Securities (USA) LLC, and Roth Capital Partners, LLC.

• Capital Allocation: The ATM program provides flexibility to align capital deployment with evolving market conditions and operational priorities.
• Shareholder Impact: The program could result in dilution if new shares are issued, but it also supports growth investments and financial stability.

Investor Considerations & Potential Share Price Impact

• Growth Acceleration: The acquisition of Lyphe and revitalization of BrewDog signal aggressive expansion in both healthcare and beverage sectors.
• Profitability Outlook: Both Lyphe and BrewDog are expected to be accretive and cash flow positive by 2027, which may positively impact future earnings and share value.
• U.S. Cannabis Opportunity: Tilray’s readiness for U.S. medical cannabis rescheduling could unlock a major new market, potentially driving significant upside.
• Financial Flexibility: The ATM program provides resources for continued investment, although potential dilution is a factor to monitor.
• Market Expansion: Tilray’s beverage and medical platforms are positioned for growth in multiple international markets, broadening revenue sources.

About Tilray Brands

Tilray Brands, Inc. is a leading global lifestyle and consumer packaged goods company operating at the nexus of cannabis, beverage, wellness, and entertainment. With over 40 brands in more than 20 countries, Tilray’s mission is to inspire joy and create memorable experiences through innovative products.

For more information: Tilray.com

Disclaimer

This article contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those projected. Investors should review Tilray’s filings with the SEC and other regulatory bodies for a detailed discussion of risks. This article is for informational purposes only and does not constitute investment advice or an offer to buy or sell securities. Always consult a financial advisor before making investment decisions.

View Tilray Brands, Inc. Historical chart here